Haemonetics Free Cash Flow (FCF) History (HAE)
Haemonetics reported $260.4M in free cash flow for fiscal 2026, an increase of 82.83% from the previous fiscal year, with a free cash flow margin of 19.52%.
View full Haemonetics company overviewHaemonetics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2026 | 2026-03-28 | $260.4M | $118.0M | +82.83% | +19.52% |
| 2025 | 2025-03-29 | $142.4M | −$1.2M | −0.82% | +10.47% |
| 2024 | 2024-03-30 | $143.6M | $61.9M | +75.73% | +10.97% |
| 2023 | 2023-04-01 | $81.7M | $6.0M | +7.89% | +6.99% |
| 2022 | 2022-04-02 | $75.8M | $4.0M | +5.56% | +7.63% |
| 2021 | 2021-04-03 | $71.8M | −$37.7M | −34.44% | +8.24% |
| 2020 | 2020-03-28 | $109.5M | $69.1M | +171.48% | +11.07% |
| 2019 | 2019-03-30 | $40.3M | −$105.2M | −72.30% | +4.17% |
| 2018 | 2018-03-31 | $145.6M | $61.9M | +74.10% | +16.10% |
| 2017 | 2017-04-01 | $83.6M | $64.1M | +329.61% | +9.43% |
| 2016 | 2016-04-02 | $19.5M | $14.5M | +292.50% | — |
| 2015 | 2015-03-28 | $5.0M | −$60.9M | −92.47% | +0.54% |
| 2014 | 2014-03-29 | $65.9M | $43.0M | +187.84% | +7.02% |
| 2013 | 2013-03-30 | $22.9M | −$39.2M | −63.16% | +2.57% |
| 2012 | 2012-03-31 | $62.1M | −$14.7M | −19.10% | +8.53% |
| 2011 | 2011-04-02 | $76.8M | $2.4M | +3.26% | +11.35% |
| 2010 | 2010-04-03 | $74.4M | $14.4M | +23.97% | +11.52% |
| 2009 | 2009-03-28 | $60.0M | — | — | — |
Haemonetics quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q1 2027 | 2026-06-27 | $44.4M | $30.8M | +225.61% | +13.09% |
| Q4 2026 | 2026-03-28 | $53.3M | −$47.6M | −47.20% | +15.38% |
| Q3 2026 | 2025-12-27 | $87.2M | $52.0M | +147.63% | +25.73% |
| Q2 2026 | 2025-09-27 | $106.3M | $66.9M | +169.88% | +32.48% |
| Q1 2026 | 2025-06-28 | $13.6M | $46.7M | — | +4.24% |
| Q4 2025 | 2025-03-29 | $100.9M | $43.5M | +75.82% | +30.52% |
| Q3 2025 | 2024-12-28 | $35.2M | $50.4M | — | +10.10% |
| Q2 2025 | 2024-09-28 | $39.4M | −$50.6M | −56.24% | +11.40% |
| Q1 2025 | 2024-06-29 | −$33.1M | −$44.5M | — | −9.84% |
| Q4 2024 | 2024-03-30 | $57.4M | $70.8M | — | +16.72% |
| Q3 2024 | 2023-12-30 | −$15.2M | −$62.8M | — | −4.52% |
| Q2 2024 | 2023-09-30 | $90.0M | $38.9M | +76.21% | +28.29% |
| Q1 2024 | 2023-07-01 | $11.4M | $14.9M | — | +3.66% |
| Q4 2023 | 2023-04-01 | −$13.4M | −$46.4M | — | −4.42% |
| Q3 2023 | 2022-12-31 | $47.6M | $11.8M | +32.98% | +15.58% |
| Q2 2023 | 2022-10-01 | $51.1M | $28.4M | +125.55% | +17.17% |
| Q1 2023 | 2022-07-02 | −$3.5M | $12.1M | — | −1.33% |
| Q4 2022 | 2022-04-02 | $32.9M | $43.0M | — | +12.43% |
| Q3 2022 | 2022-01-01 | $35.8M | −$21.1M | −37.16% | +13.77% |
| Q2 2022 | 2021-10-02 | $22.6M | $1.8M | +8.80% | +9.44% |
| Q1 2022 | 2021-07-03 | −$15.6M | −$19.7M | — | −6.83% |
| Q4 2021 | 2021-04-03 | −$10.1M | −$45.8M | — | −4.48% |
| Q3 2021 | 2020-12-26 | $56.9M | −$2.0M | −3.35% | +23.68% |
| Q2 2021 | 2020-09-26 | $20.8M | $388,000 | +1.90% | +9.94% |
| Q1 2021 | 2020-06-27 | $4.1M | $9.7M | — | +2.10% |
| Q4 2020 | 2020-03-28 | $35.8M | $28.8M | +416.61% | +14.99% |
| Q3 2020 | 2019-12-28 | $58.9M | $30.0M | +103.63% | +22.74% |
| Q2 2020 | 2019-09-28 | $20.4M | $11.6M | +130.33% | +8.09% |
| Q1 2020 | 2019-06-29 | −$5.6M | −$1.2M | — | −2.36% |
| Q4 2019 | 2019-03-30 | $6.9M | −$31.6M | −82.03% | +2.78% |
| Q3 2019 | 2018-12-29 | $28.9M | −$9.9M | −25.51% | +11.69% |
| Q2 2019 | 2018-09-29 | $8.9M | −$34.6M | −79.61% | +3.67% |
| Q1 2019 | 2018-06-30 | −$4.4M | −$29.1M | — | −1.92% |
| Q4 2018 | 2018-03-31 | $38.5M | $19.6M | +103.20% | +16.49% |
| Q3 2018 | 2017-12-30 | $38.8M | $2.5M | +6.93% | +16.59% |
| Q2 2018 | 2017-09-30 | $43.5M | $23.4M | +116.20% | +19.30% |
| Q1 2018 | 2017-07-01 | $24.7M | $16.5M | +200.68% | +11.71% |
| Q4 2017 | 2017-04-01 | $19.0M | −$5.8M | −23.30% | — |
| Q3 2017 | 2016-12-31 | $36.3M | $28.2M | +347.69% | — |
| Q2 2017 | 2016-10-01 | $20.1M | $18.5M | +1136.63% | — |
| Q1 2017 | 2016-07-02 | $8.2M | $23.2M | — | — |
| Q4 2016 | 2016-04-02 | $24.7M | −$8.9M | −26.46% | — |
| Q3 2016 | 2015-12-26 | $8.1M | $10.9M | — | — |
| Q2 2016 | 2015-09-26 | $1.6M | $4.2M | — | — |
| Q1 2016 | 2015-06-27 | −$15.0M | $8.4M | — | — |
| Q4 2015 | 2015-03-28 | $33.6M | −$10.4M | −23.64% | — |
| Q3 2015 | 2014-12-27 | −$2.8M | −$3.1M | — | — |
| Q2 2015 | 2014-09-27 | −$2.5M | −$17.6M | — | — |
| Q1 2015 | 2014-06-28 | −$23.3M | −$32.1M | — | — |
| Q3 2014 | 2013-12-28 | $44.0M | $37.0M | +526.83% | — |
| Q1 2014 | 2013-06-29 | $310,000 | $8.2M | — | — |
| Q4 2013 | 2013-03-30 | $15.0M | −$2.7M | −15.21% | — |
| Q3 2013 | 2012-12-29 | $8.7M | −$7.0M | −44.47% | — |
| Q2 2013 | 2012-09-29 | $7.0M | −$6.3M | −47.46% | — |
| Q1 2013 | 2012-06-30 | −$7.9M | −$23.2M | — | — |
| Q4 2012 | 2012-03-31 | $17.7M | −$2.7M | −13.30% | — |
| Q3 2012 | 2011-12-31 | $15.7M | −$20.4M | −56.58% | — |
| Q2 2012 | 2011-10-01 | $13.4M | −$8.5M | −38.96% | — |
| Q1 2012 | 2011-07-02 | $15.3M | $17.0M | — | — |
| Q4 2011 | 2011-04-02 | $20.5M | −$4.8M | −19.02% | — |
| Q3 2011 | 2011-01-01 | $36.1M | $15.6M | +76.20% | — |
| Q2 2011 | 2010-10-02 | $21.9M | −$2.2M | −9.13% | — |
| Q1 2011 | 2010-07-03 | −$1.7M | −$6.2M | — | — |
| Q4 2010 | 2010-04-03 | $25.3M | — | — | — |
| Q3 2010 | 2009-12-26 | $20.5M | — | — | — |
| Q2 2010 | 2009-09-26 | $24.1M | — | — | — |
| Q1 2010 | 2009-06-27 | $4.5M | — | — | — |
Haemonetics free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $71.8M to $260.4M, a compound annual growth rate of 29.41%. Haemonetics's latest reported quarter, Q1 2027, generated $44.4M in free cash flow, an increase of 225.61% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Haemonetics filings at SEC.gov ↗